April 17, 2023
Azome Therapeutics, an early stage drug discovery company, announced the appointment of Stavros Garantziotis, MD to its Scientific Advisory Board. Dr. Garantziotis is the Medical Director of the NIEHS Clinical Research Unit, and Adjunct Professor in the Department of Medicine at Duke University Medical School.
April 7, 2023
Azome Therapeutics, an early stage drug discovery company, announced the appointment of Ulrich H. Von Andrian, MD to its Scientific Advisory Board. Dr. Von Andrian is the Edward Mallinckrodt Jr. Professor of Immunopathology, Microbiology and Immunobiology at Harvard Medical School, and Senior Investigator at the Von Andrian Lab at Boston Children's Hospital.
March 6, 2023
Azome Therapeutics, an early-stage drug discovery company, announced the execution of an exclusive US patent license. Under the agreement, Azome acquired exclusive rights to patent US10562935 entitled “Stapled peptides and uses thereof” and related EU patent applications. The intellectual property includes substantial and specific composition of matter and method of use protection for the company’s core RHAMM antagonist technology platform.
